tetano
Editor, Senior Moderator
Diabetol Int
. 2023 Jul 31;14(4):422-426.
doi: 10.1007/s13340-023-00648-8. eCollection 2023 Oct. Anti-GAD antibody-positive fulminant type 1 diabetes developed following SARS-CoV-2 vaccination
Tomohito Izumi[SUP] 1 [/SUP], Hironobu Takahashi[SUP] 1 [/SUP], Hironori Takahashi[SUP] 1 [/SUP]
Affiliations
Vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been used worldwide since the 2020 coronavirus pandemic. However, several negative side-effects of these vaccines have been reported. Herein, we present a case of a patient with fulminant type 1 diabetes that developed shortly after administration of the SARS-CoV-2 vaccine. A 47-year-old man with no medical history presented with hyperglycemia-related symptoms shortly after receiving the third messenger ribonucleic acid SARS-CoV-2 vaccine. Based on hyperglycemia, diabetic ketoacidosis at onset, relatively low hemoglobin A1c levels, and complete depletion of endogenous insulin secretion, the patient was diagnosed with fulminant type 1 diabetes and insulin therapy was initiated. Through human leukocyte antigen genotyping, the disease-susceptible alleles for type 1 diabetes, DRB1*04:05 and DQB1*04:01, were identified. The patient tested positive for serum anti-glutamic acid decarboxylase antibodies, which are normally negative for fulminant type 1 diabetes, implying that immunomodulation triggered by SARS-CoV-2 vaccination influenced the onset of type 1 diabetes.
Keywords: Diabetic ketoacidosis; Fulminant type 1 diabetes; SARS-CoV-2; Vaccine.
. 2023 Jul 31;14(4):422-426.
doi: 10.1007/s13340-023-00648-8. eCollection 2023 Oct. Anti-GAD antibody-positive fulminant type 1 diabetes developed following SARS-CoV-2 vaccination
Tomohito Izumi[SUP] 1 [/SUP], Hironobu Takahashi[SUP] 1 [/SUP], Hironori Takahashi[SUP] 1 [/SUP]
Affiliations
- PMID: 37781472
- PMCID: PMC10533421 (available on 2024-07-31)
- DOI: 10.1007/s13340-023-00648-8
Vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been used worldwide since the 2020 coronavirus pandemic. However, several negative side-effects of these vaccines have been reported. Herein, we present a case of a patient with fulminant type 1 diabetes that developed shortly after administration of the SARS-CoV-2 vaccine. A 47-year-old man with no medical history presented with hyperglycemia-related symptoms shortly after receiving the third messenger ribonucleic acid SARS-CoV-2 vaccine. Based on hyperglycemia, diabetic ketoacidosis at onset, relatively low hemoglobin A1c levels, and complete depletion of endogenous insulin secretion, the patient was diagnosed with fulminant type 1 diabetes and insulin therapy was initiated. Through human leukocyte antigen genotyping, the disease-susceptible alleles for type 1 diabetes, DRB1*04:05 and DQB1*04:01, were identified. The patient tested positive for serum anti-glutamic acid decarboxylase antibodies, which are normally negative for fulminant type 1 diabetes, implying that immunomodulation triggered by SARS-CoV-2 vaccination influenced the onset of type 1 diabetes.
Keywords: Diabetic ketoacidosis; Fulminant type 1 diabetes; SARS-CoV-2; Vaccine.